Lyell Immunopharma, Inc. is a late stage clinical cell therapy company advancing a pipeline of proprietary next generation autologous CAR T cell product candidates for patients with cancer; the company focuses on hematologic malignancies and solid tumors aiming to realize the curative potential of cell therapy.

Lyell Immunopharma, Inc. has not yet commercialized any products and does not generate product revenue; its financial resources consist of upfront and milestone payments from licensing agreements and proceeds from equity offerings.

In the field of CAR T cell therapies Lyell Immunopharma, Inc. positions itself as a developer of next generation products that seek to improve response rates and durability over first generation approved therapies; key competitors include Gilead Sciences with Yescarta Bristol Myers Squibb with Breyanzi and Novartis with Kymriah among others; the company differentiates itself through dual targeting CD19 CD20 CAR constructs CD62L positive enrichment and proprietary technologies designed to reduce T cell exhaustion and enhance stemness.

Lyell Immunopharma, Inc. intends to serve patients with relapsed or refractory large B cell lymphoma and metastatic colorectal cancer among other indications; its future customers will include hospitals cancer treatment centers and healthcare providers that administer CAR T cell therapies; no specific customer names are disclosed in the filing.